Aquestive Therapeutics, Inc.
corporate_fare Company Profile
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for AQST at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for AQST spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- Aquestive Investor Deck Details $95M Contingent Funding Access Ahead of March 2027 Anaphylm PDUFA
- Aquestive 10-Q: Cash Falls to $90.3M, Stockholders' Deficit Widens to $70.8M
- Aquestive Q3 Revenue Falls 41% to $7.6M; Anaphylm PDUFA Set for March 16, 2027
- Q3 Revenue Drops 41% to $7.6M as Net Loss Widens
- FDA Accepts Anaphylm NDA Resubmission, Sets March 16, 2027 Decision Date
Financial Snapshot
Short Interest & Short Volume
13.24 days to coverFINRA reported short interest of 29,318,686 shares in AQST as of the October 30, 2026 settlement, a 6.2% increase from the prior period — about 13.2 days to cover at its recent average daily volume. On November 20, 2026, 67.8% of AQST volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AQST, detected from its recent SEC filings.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →